ADVICENNE Aktie

>ADVICENNE Performance

1 Woche: 0%

1 Monat: -1,2%

3 Monate: +18,6%

6 Monate: -10,5%

1 Jahr: -9,4%

laufendes Jahr: -10,3%

>ADVICENNE Aktie

Name:

ADVICENNE (PROM.) EO-,20

Land:

Frankreich

Sektor:

Gesundheit

ISIN/ Wkn:

FR0013296746 / A2H8SU

Symbol/ Ticker:

3MM (Frankfurt)

Kürzel:

FRA:3MM, ETR:3MM, 3MM:GR

Index:

Webseite:

https://advicenne.com/

Marktkapitalisierung:

21.91 Mio. EUR

Umsatz:

5.27 Mio. EUR

EBITDA:

-6.53 Mio. EUR

Gewinn je Aktie:

-0.48 EUR

Schulden:

18.19 Mio. EUR

Liquide Mittel:

3.25 Mio. EUR

Umsatz-/ Gewinnwachstum:

-2.6% / -

KGV/ KGV lG:

- / -

KUV/ KBV/ PEG:

7.33 / - / -

Gewinnm./ Eigenkapitalr.:

-122.7% / -

Dividende je Aktie:

Dividendenrendite/ -schätzung:

- / -

Insiderhandel:

Suchwörter:

ADVICENNE

Letzte Datenerhebung:

06.07.25

>ADVICENNE Eigentümer

Aktien: 12.28 Mio. St.

f.h. Aktien: 6.62 Mio. St.

Insider Eigner: 3.53%

Instit. Eigner: 47.24%

Leerverk. Aktien: -

>ADVICENNE Peer Group

AMPLITUDE SURGICAL

ATON

BIOPHYTIS

BOIRON

LNA SANTE

ONCODESIGN

QUANTUM GENOMICS

SMAIO

SPINEWAY

VALERIO THERAPEUTICS

>ADVICENNE Chart & Kurs - Stuttgart

>ADVICENNE News

02.07.25 - 00:21	XFRA: CAPITAL ADJUSTMENT INFORMATION - 02.07.2025 - EQUBF_01 (XETRA)
	Das Instrument 3MM FR0013296746 ADVICENNE (PROM.) EO-,20 EQUITY wird ex Kapitalmassnahme gehandelt am 02.07.2025 The instrument 3MM FR0013296746 ADVICENNE (PROM.) EO-,20 EQUITY is traded ex capital adjustment on 02.07.2025...

29.04.25 - 18:03

Advicenne 2024 Universal Registration Document Made Available (Business Wire)

PARIS--(BUSINESS WIRE)--Regulatory News: Advicenne (Euronext Growth Paris ALDVI - FR0013296746), a specialty pharmaceutical company dedicated to the development and commercialization of innovative treatments for those suffering from rare renal diseases, announces today that its 2024 Universal Registration Document has been filed with the French Autorité des Marchés Financiers (AMF). The Universal Registration Document includes the annual report, the management report, the Board of Directors' report on corporate governance and the Statutory Auditors' reports. It also contains a description of the share buyback program. The Universal Registration Document is available on Advicenne's website (www.advicenne.com) in the Investors/Financial Information section and on the AMF website (www.amf-france.org). About Advicenne Advicenne (Euronext: ALDVI) is a specialty pharmaceutical company founded in 2007, specializing in the development of innovative treatments in Nephrology. Its lead product Sibnayal® (ADV71...

27.03.25 - 19:18

Advicenne: Fiscal Year 2024 Marked by the Satisfactory Commercial Performance of Sibnayal® in Europe and Development in the United States (Business Wire)

Total product sales of Advicenne up 9.4% to €4.9m Operating cash consumption below €1M by 2025 and significant improvement in cash flow Cash position of €3.2 million on December 31, 2024, with a financing horizon of end-June 2025 European in-market sales of Sibnayal® up over 130% to €6.0M and royalties received in excess of €0.5M Major regulatory advances for ADV7103 / Sibnayal® in the United States in its two indications (dRTA and cystinuria) Favorable outlook with the filing of ADV7103 in dRTA in the United States, expected in Q3 2025 PARIS--(BUSINESS WIRE)--Regulatory News: Advicenne (Euronext Growth Paris ALDVI – FR0013296746) a specialty pharmaceutical company dedicated to the development and commercialization of innovative treatments for those suffering from rare renal diseases, announces today its 2024 financial results, and provides an update on its activities. The financial statements for the year 2024 were approved by the Board of Directors at its meeting on March 27, 2025. The aud...

23.01.25 - 18:33

Advicenne Announces 2024 Gross Sales1 (Business Wire)

2024 Gross sales reported at €4.8 million, up 9.2%. Gross sales of Sibnayal® (potassium citrate / potassium bicarbonate) in France recorded an impressive 40% growth. Royalties for 2024 are estimated at €0.5 million in addition to reported gross sales. End-market estimated global sales of Sibnayal® in Europe and Middle East, reaching €6.0 million, up 135% compared to 2023. PARIS--(BUSINESS WIRE)--Regulatory News: Advicenne (Euronext Growth Paris ALDVI – FR0013296746) a specialty pharmaceutical company dedicated to the development and commercialization of innovative treatments for those suffering from rare renal diseases, today announces that gross sales reached €4.8 million for the 2024 financial year, up 9.2% on the previous year. Gross sales do not include royalties from partners on sales in their respective territories, estimated at €0.5 million for 2024. Sibnayal® mostly drove the growth with reported gross sales of €2.2 million, up by almost 14%. In France, the performance was solid, ...

01.10.24 - 07:09	Advicenne achieves major milestones in the US thanks to several positive FDA opinions on ADV7103 (Business Wire)
	Um den gesamten Artikel unter morningstar.com zu lesen, klicken Sie bitte auf die Überschrift...

18.09.24 - 18:21	Advicenne Reports Its First Half Financial Results as of June 30, 2024, and Updates on Its Activities (Business Wire)
	Um den gesamten Artikel unter morningstar.com zu lesen, klicken Sie bitte auf die Überschrift...

18.07.24 - 18:33	Advicenne Announces an 8.8% Increase in Gross Sales for H1 2024 and Provides an Update on Its Activities (Business Wire)
	Um den gesamten Artikel unter morningstar.com zu lesen, klicken Sie bitte auf die Überschrift...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Männer sind wie Luft, zwar versaut, aber unentbehrlich. - Michelle Pfeiffer

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram